Provided by
| Consensus (mean) in EUR million | FY 2025 | FY 2026 E | FY 2027 E | FY 2028 E |
|---|---|---|---|---|
| Orders received | 5,216 | 4,883 | 5,353 | 5,670 |
| - Biomaterial Solutions and Services | 3,716.0 | 3,237.4 | 3,499.9 | 3,725.1 |
| - Process Performance Solutions | 1,500.0 | 1,646.2 | 1,853.7 | 1,945.0 |
| Net sales | 5,197 | 5,282 | 5,402 | 5,629 |
| - Biomaterial Solutions and Services | 3,716.0 | 3,663.4 | 3,556.6 | 3,648.6 |
| - Process Performance Solutions | 1,481.0 | 1,624.4 | 1,822.6 | 1,909.2 |
| Comparable EBITA | 620 | 619 | 681 | 733 |
| - Biomaterial Solutions and Services | 381.0 | 352.8 | 379.0 | 406.2 |
| - Process Performance Solutions | 290.0 | 312.0 | 346.3 | 370.2 |
| Comparable EBITA Margin (%) | 11.9% | 11.7% | 12.6% | 13.0% |
| - Biomaterial Solns. and Servs. | 10.3% | 9.6% | 10.6% | 11.1% |
| - Process Perf. Solns. | 19.6% | 19.2% | 19.0% | 19.4% |
| Adjusted EPS | 1.82 | 2.03 | 2.27 | 2.51 |
| Dividend per share | 1.35 | 1.41 | 1.49 | 1.57 |